» Articles » PMID: 9886305

A New Sickle Cell Disease Phenotype Associating Hb S Trait, Severe Pyruvate Kinase Deficiency (PK Conakry), and an Alpha2 Globin Gene Variant (Hb Conakry)

Overview
Journal Br J Haematol
Specialty Hematology
Date 1999 Jan 14
PMID 9886305
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

A Guinean woman, heterozygous for haemoglobin (Hb) S, was studied because of episodes of marked anaemia, repeated typical metaphyseal painful crises and haemosiderosis. Her sickling syndrome resulted from the association of Hb S trait with a severe pyruvate kinase deficiency leading to a 2,3-DPG concentration of twice normal levels. Sequence of the PK-R gene revealed an undescribed mutation in the homozygous or hemizygous state within exon 5 (nucleotide 2670 C-->A), leading to the interchange of Ser 130 into Tyr (PK Conakry). In addition, the patient carried a new haemoglobin variant, Hb Conakry [alpha80(F1) Leu-->Val], which seemed to have a mild effect. The high intraerythrocytic 2,3-DPG concentration induced by the PK deficiency resulted in a decreased oxygen affinity which favoured sickling to a level almost similar to that of Hb S/C compound heterozygous patients. This was confirmed by oxygen binding measurements of Hb A/Hb S erythrocytes in which 2,3-DPG content was modified in vitro. Hysteresis between deoxy- and reoxygenation curves, as well as increase in the n(max) value, demonstrated that the extent of HbS polymerization in the propositus was almost the same as that of RBCs from a homozygous sickle cell patient or those of an A/S heterozygous patient with an artificial in vitro increase of 2,3-DPG concentration.

Citing Articles

Recent developments in the use of pyruvate kinase activators as a new approach for treating sickle cell disease.

Parekh D, Eaton W, Thein S Blood. 2023; 143(10):866-871.

PMID: 38118071 PMC: 10940061. DOI: 10.1182/blood.2023021167.


Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease.

Xu J, Vercellotti G Hematology Am Soc Hematol Educ Program. 2023; 2023(1):107-113.

PMID: 38066891 PMC: 10727103. DOI: 10.1182/hematology.2023000467.


PYK-SubstitutionOME: an integrated database containing allosteric coupling, ligand affinity and mutational, structural, pathological, bioinformatic and computational information about pyruvate kinase isozymes.

Swint-Kruse L, Dougherty L, Page B, Wu T, ONeil P, Prasannan C Database (Oxford). 2023; 2023.

PMID: 37171062 PMC: 10176505. DOI: 10.1093/database/baad030.


Metabolic Reprogramming in Sickle Cell Diseases: Pathophysiology and Drug Discovery Opportunities.

Alramadhani D, Aljahdali A, Abdulmalik O, Daniel Pierce B, Safo M Int J Mol Sci. 2022; 23(13).

PMID: 35806451 PMC: 9266828. DOI: 10.3390/ijms23137448.


Mitapivat increases ATP and decreases oxidative stress and erythrocyte mitochondria retention in a SCD mouse model.

Quezado Z, Kamimura S, Smith M, Wang X, Heaven M, Jana S Blood Cells Mol Dis. 2022; 95:102660.

PMID: 35366607 PMC: 9148618. DOI: 10.1016/j.bcmd.2022.102660.